Session » Rheumatoid Arthritis - Clinical Aspects IV: Biomarkers, Disease Progression and Treatment Response

Date: Tuesday, November 10, 2015

Time: 2:30PM-4:00PM

Meeting: 2015 ACR/ARHP Annual Meeting

2:30PM-4:00PM: Abstract Number: 3100

Anti-RA33 Citrullinated/Native Double-Reactive Antibodies Identify Patients with the Highest Risk of Radiographic Progression in Rheumatoid Arthritis

2:30PM-4:00PM: Abstract Number: 3103

Carbamylated Human Albumin Is One of the Target Antigens of Anti-Carbamylated Protein Antibodies

2:30PM-4:00PM: Abstract Number: 3099

Differential Effects of IL-6 Blockade Tocilizumab and TNF Inhibitors on the Reduced Angiogenesis and Lining Layer Degeneration in Synovial Tissues from Patients with Rheumatoid Arthritis

2:30PM-4:00PM: Abstract Number: 3102

Increasing Circulating Adiponectin after DMARD Initiation Is Associated with Radiographic Progression in Early Aggressive RA, Regardless of Treatment Strategy

2:30PM-4:00PM: Abstract Number: 3101

Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) and Sclerostin Are Related to Joint Destruction in Early Rheumatoid Arthritis Unrelated to Polymorphisms of the Genes

2:30PM-4:00PM: Abstract Number: 3098

Synovial Lymphocytic Aggregates Associate with Highly Active RA and Predict Erosive Disease at 12 Months: Results from the Pathobiology of Early Arthritis Cohort

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].